Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

Fig. 3

Survival of the patients in the largest histological subgroups. Kaplan-Meier curves showing overall survival (OS) and progression-free survival (PFS) according to the risk groups among the patients with non-small cell lung cancer (NSCLC) (a, b), melanoma (c, d) and renal cell carcinoma (RCC) (e, f)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us